Spermosens AB (SPERM.ST)
SEK 0.01
(4.76%)
SEK 0.01
(4.76%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 5.02 Million SEK | 521.91% |
| 2022 | 808 Thousand SEK | 113.03% |
| 2021 | -6.2 Million SEK | -446.42% |
| 2020 | 1.79 Million SEK | 452.36% |
| 2019 | -508 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -2.18 Million SEK | -124.97% |
| 2024 Q3 | 497 Thousand SEK | 122.74% |
| 2024 Q1 | 8.75 Million SEK | 74.19% |
| 2023 Q4 | 5.02 Million SEK | 390.24% |
| 2023 FY | 5.02 Million SEK | 521.91% |
| 2023 Q3 | 1.02 Million SEK | 118.13% |
| 2023 Q2 | -5.65 Million SEK | 52.48% |
| 2023 Q1 | -11.89 Million SEK | -1572.15% |
| 2022 Q1 | -73 Thousand SEK | 98.82% |
| 2022 FY | 808 Thousand SEK | 113.03% |
| 2022 Q4 | 808 Thousand SEK | 115.78% |
| 2022 Q3 | -5.12 Million SEK | 55.21% |
| 2022 Q2 | -11.43 Million SEK | -15557.53% |
| 2021 Q4 | -6.2 Million SEK | 52.38% |
| 2021 Q1 | 4.36 Million SEK | 143.91% |
| 2021 Q3 | -13.02 Million SEK | 26.24% |
| 2021 Q2 | -17.65 Million SEK | -504.35% |
| 2021 FY | -6.2 Million SEK | -446.42% |
| 2020 Q4 | 1.79 Million SEK | 0.0% |
| 2020 FY | 1.79 Million SEK | 452.36% |
| 2019 FY | -508 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AroCell AB (publ) | -50.72 Million SEK | 109.907% |
| Devyser Diagnostics AB (publ) | -188.09 Million SEK | 102.671% |
| Immunovia AB (publ) | -72.5 Million SEK | 106.931% |
| Prostatype Genomics AB (publ) | -2.61 Million SEK | 292.161% |
| SenzaGen AB | -15.95 Million SEK | 131.503% |